Sherkow publishes new article on new genomic technologies 

Professor Jacob Sherkow is co-author of a new article in International Review of Intellectual Property and Competition Law focused on new genomic technologies. “Intellectual Property, New Genomic Technologies and Plant Innovation: Clearing Innovation Pathways” focuses on how new genomic technologies may revolutionize agriculture, but how United States and European Union patent protections may hinder their implementation.

Sherkow provides Master Class presentation

In October, Professor Jacob Sherkow gave a Master Class presentation at the University of Copenhagen on Advanced Biotechnology and Advanced Regulation, that assessed recent biotechnological advancements with regulatory paradigms in the United States and the European Union. The class is a tuition-free, ten-session online program for legal, medical, scientific, and policy professionals working at the frontier of health & life-science innovation. Each class consists of a 3-hour session of expert teaching with case discussion and a question and answer session.

Sherkow helps correct record on peptides

Influencers have shared viewpoints widely on peptides across the internet, and recently a panel that advises the FDA voted to loosen restrictions on vetting of experimental peptides. To help consumers understand fact from fiction on peptides, USA Today highlighted the myths and red flags around these drugs. Professor Jacob Sherkow lent his expertise to the article, helping to dispel falsehoods.

Chemistry World quotes Sherkow on Merck antibiotic withdrawal

Merck & Co.’s decision to discontinue its intravenous antibiotic combination Recarbrio has led to a shortage of medicine used to treat antibiotic-resistant infections. In dissecting the issue, Chemistry World quoted Professor Jacob Sherkow, an expert in patents, about whether a generic drug could be manufactured to make up for the shortage. “These are very complicated drugs to manufacture, often needing their own manufacturing facility to avoid cross-contamination, which is an expensive endeavor for a generics company,” he said.

Sherkow quoted in Bloomberg on seed technology patent case

Corteva Inc. v. Inari Agriculture Inc. was a closely watched case in the world of biological materials patents. When it ended in a settlement, however, it was a missed opportunity for the courts to come to a ruling on patents for plant varieties. Speaking with Bloomberg, Professor Jacob Sherkow explained that Inari’s decision to settle and place biological materials it obtained into a repository might make similar deals more appealing in future cases. ““You can deposit and get your patents without worrying that everyone will just design around,” he said.

Sherkow publishes paper on genome-edited microbes

In the search for new means of sustainability in agriculture, genome-edited microbes represent a promising tool. In a new paper, Professor Jacob Sherkow investigates the regulatory issues and differences between the US and EU approaches, including recent EU legislation. The article suggests that there are lessons to be learned on both sides and provides recommendations for future regulations.

SCOTUS made right decision in Hikma, Sherkow writes

In an new essay on Health Affairs, Professor Jacob Sherkow writes that the U.S. Supreme Court made the correct decision in Hikma Pharmaceuticals v. Amarin Pharma, giving generic drug manufacturers important protection against patent suits based on labeling approved by the Food and Drug Administration (FDA). This decision will “help preserve patient access to lower-cost medicines,” he writes; however, it also shifts pressure onto FDA, which does not interpret patent claims or decide whether future prescribing will infringe.

Undark quotes Sherkow on FDA regulation of peptides

In order to bring a drug to market, manufacturers have long been required to demonstrate safety and effectiveness in clinical trials; however, Health and Human Services Secretary Robert F. Kennedy Jr. would like to change the Food and Drug Administration’s role to make it easier access experimental medicine. In an article on the FDA considering allowing pharmacies to compound and sell seven unapproved peptides, Undark quoted Professor Jacob Sherkow who called this “a brave new world” in which some substances may “go forward without any rigorous scientific evidence base.”

Sherkow to speak about indirect patent infringement at 15th Waseda-Penn Global Patent Law Conference

On Monday, June 1, Professor Jacob Sherkow will deliver a lecture at the 15th Waseda-Penn Global Patent Law Conference in Japan. His talk will introduce the fundamentals of indirect patent infringement under U.S. law, with a focus on inducement doctrine under 35 U.S.C. § 271(b). Drawing on recent litigation and scholarship — including the “infringement by label” debate highlighted in the Supreme Court case Hikma v. Amarin — the talk will critically examine how current case law risks expanding inducement liability beyond its traditional requirement of active encouragement and causation. In doing so, the lecture will highlight broader questions about the proper limits of indirect infringement and the role of regulatory contexts in shaping liability—issues that also resonate in ongoing Japanese debates on the scope and structure of secondary patent liability.

College of Law
504 East Pennsylvania Avenue
Champaign, IL 61820
(217) 333-0931